Patricia Pérez-Galán
Grup de recerca
- Microambient en la patogènesi i teràpia del limfoma Junior group leader (R3B)
Publicacions destacades
-
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
Autors: Vidal-Crespo A; Matas-Céspedes A; Rodriguez V; Rossi C; Valero JG; Serrat N; Sanjuan-Pla A; Menéndez P; Roué G; López-Guillermo A; Giné E; Campo E; Colomer D; Bezombes C; van Bueren JL; Chiu C; Doshi P; Pérez-Galán P.Referència: Haematologica 2020. -
Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions
Autors: Castella M, Boronat A, Martín-Ibáñez R, Rodríguez V, Suñé G, Caballero M, Marzal B, Pérez-Amill L, Martín-Antonio B, Castaño J, Bueno C, Balagué O, González-Navarro EA, Serra-Pages C, Engel P, Vilella R, Benitez-Ribas D, Ortiz-Maldonado V, Cid J, Tabera J, Canals JM, Lozano M, Baumann T, Vilarrodona A, Trias E, Campo E, Menendez P, Urbano-Ispizua Á, Yagüe J, Pérez-Galán P, Rives S, Delgado J, Juan M .Referència: Molecular Therapy-Methods & Clinical Development 2019. -
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia
Autors: Lee-Vergés E, Hanna BS, Yazdanparast H, Rodríguez V, Rodríguez ML, Giró A, Vidal-Crespo A, Rosich L, Amador V, Aymerich M, Villamor N, Delgado J, Lichter P, Pérez-Galán P, López-Guerra M, Campo E, Seiffert M, Colomer D .Referència: International Journal Of Cancer 2019. -
Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma
Autors: Rossi C; Gravelle P; Decaup E; Bordenave J; Poupot M; Tosolini M; Franchini DM; Laurent C; Morin R; Lagarde JM; Ysebaert L; Ligat L; Jean C; Savina A; Klein C; Céspedes AM; Perez-Galan P; Fournié JJ; Bezombes C.Referència: Oncoimmunology 2019. -
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status
Autors: Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Giné E, Navarro A, Beà S, Campo E, López-Guillermo A, Lopez-Guerra M, Roué G, Colomer D, Pérez-Galán P .Referència: Haematologica 2017. -
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia
Autors: Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, Colomer D, Roué G, Wiestner A, Parren PW, Doshi P, van Bueren JL, Pérez-Galán P .Referència: Clinical Cancer Research 2017. -
Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Autors: Matas-Cespedes, Alba; Rodriguez, Vanina; Kalko, Susana G; Vidal-Crespo, Anna; Rosich, Laia; Casserras, Teresa; Balsas, Patricia; Villamor, Neus; Gine, Eva; Campo, Elias; Roue, Gael; Lopez-Guillermo, Armando; Colomer, Dolors; Perez-Galan, Patricia.Referència: Clinical Cancer Research 2014. -
Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
Autors: Herman, S E M; Sun, X; Mcauley, E M; Hsieh, M M; Pittaluga, S; Raffeld, M; Liu, D; Keyvanfar, K; Chapman, C M; Chen, J; Buggy, J J; Aue, G; Tisdale, J F; Perez-Galan, P; Wiestner, A.Referència: Leukemia 2013. -
ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
Autors: Chapman, Colby M; Sun, Xiameng; Roschewski, Mark; Aue, Georg; Farooqui, Mohamed; Stennett, Lawrence; Gibellini, Federica; Arthur, Diane; Perez-Galan, Patricia; Wiestner, Adrian.Referència: Clinical Cancer Research 2012. -
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Autors: Herishanu Y; Pérez-Galán P; Liu D; Biancotto A; Pittaluga S; Vire B; Gibellini F; Njuguna N; Lee E; Stennett L; Raghavachari N; Liu P; McCoy J; Raffeld M; Stetler-Stevenson M; Yuan C; Sherry R; Arthur D; Maric I; White T; Marti G; Munson P; Wilson W; Wiestner A.Referència: Blood 2011.
Projectes destacats
-
Tailored immunotherapies in 3D models of Follicular Lymphoma (TAIFOL)
Investigador/a principal: Patricia Pérez GalánFinançador: Janssen Pharmaceuticals ; Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Fundació La Marató de TV3Durada: 01/04/2020 -
Characterization of duvelisib activity in follicular lymphoma and macrophages crosstalk
Investigador/a principal: Patricia Pérez GalánFinançador: Janssen Pharmaceuticals ; Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); VerastemDurada: 01/01/2020 - 31/12/2020 -
Multi-cellular interactions in the progression of chronic inflammatory diseases and lymphoproliferative disorders: 3D models to investigate targeted immune therapies -3DIMMUNETARGET
Investigador/a principal: Patricia Pérez Galán, Maria Cinta Cid Xutgla, Patricia Pérez GalánFinançador: Ministerio de Economia y Competitividad (MINECO) (Patrocinador)Codi: SAF 2017- 88275-RDurada: 01/01/2018 - 31/12/2020 -
Cross-border network of personalized immunotherapies in Non-Hodgkin Lymphoma -IMLINFO (POCTEFA-INTERREG). Proyecto financiado por Fondo Europeo de Desarrollo Regional (FEDER)
Investigador/a principal: Patricia Pérez GalánFinançador: INTERREG V-POCTEFACodi: EFA281/16Durada: 01/01/2018 - 31/12/2021 -
Crosstalk between lymphocytes and their microenvironment in chronic inflammatory diseases and lymphoproliferative disorders as a target for new therapeutic intervention
Investigador/a principal: Patricia Pérez GalánFinançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Ministerio de Economia y Competitividad (MINECO) ; PROYECTOS I+D+I RETOS INVESTIGACIÓN (Programa financiador competitivo)Codi: SAF2014-57708-RDurada: 01/10/2015 - 30/09/2018